These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19362995)

  • 1. Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum.
    Bennetto-Hood C; Bryson YJ; Stek A; King JR; Mirochnick M; Acosta EP
    HIV Clin Trials; 2009; 10(1):41-7. PubMed ID: 19362995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353.
    Bryson YJ; Mirochnick M; Stek A; Mofenson LM; Connor J; Capparelli E; Watts DH; Huang S; Hughes MD; Kaiser K; Purdue L; Asfaw Y; Keller M; Smith E;
    HIV Clin Trials; 2008; 9(2):115-25. PubMed ID: 18474496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples.
    Hirt D; Urien S; Jullien V; Firtion G; Chappuy H; Rey E; Pons G; Mandelbrot L; Treluyer JM
    Br J Clin Pharmacol; 2007 Nov; 64(5):634-44. PubMed ID: 17892516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy.
    Kakehasi FM; Tupinambás U; Cleto S; Aleixo A; Lin E; Melo VH; Aguiar RA; Pinto JA
    AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1515-20. PubMed ID: 18160009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of combined zidovudine and lamivudine compared with that of combined zidovudine, lamivudine and nelfinavir in asymptomatic and early symptomatic HIV-infected children.
    Moolasart P; Likanonsakul S
    Southeast Asian J Trop Med Public Health; 2002 Jun; 33(2):280-7. PubMed ID: 12236426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus.
    Chappuy H; Tréluyer JM; Rey E; Dimet J; Fouché M; Firtion G; Pons G; Mandelbrot L
    Am J Obstet Gynecol; 2004 Aug; 191(2):558-62. PubMed ID: 15343237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
    Else LJ; Taylor S; Back DJ; Khoo SH
    Antivir Ther; 2011; 16(8):1139-47. PubMed ID: 22155898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy.
    Haaland RE; Otieno K; Martin A; Katana A; Dinh C; Slutsker L; Menendez C; Gonzalez R; Williamson J; Heneine W; Desai M
    AIDS Res Hum Retroviruses; 2018 Nov; 34(11):912-915. PubMed ID: 30173559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
    Ford J; Cornforth D; Hoggard PG; Cuthbertson Z; Meaden ER; Williams I; Johnson M; Daniels E; Hsyu P; Back DJ; Khoo SH
    Antivir Ther; 2004 Feb; 9(1):77-84. PubMed ID: 15040539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.
    Yeh RF; Rezk NL; Kashuba AD; Dumond JB; Tappouni HL; Tien HC; Chen YC; Vourvahis M; Horton AL; Fiscus SA; Patterson KB
    Antimicrob Agents Chemother; 2009 Jun; 53(6):2367-74. PubMed ID: 19307360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies.
    Maguire M; Gartland M; Moore S; Hill A; Tisdale M; Harrigan R; Kleim JP
    AIDS; 2000 Jun; 14(9):1195-201. PubMed ID: 10894284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    Siegfried N; van der Merwe L; Brocklehurst P; Sint TT
    Cochrane Database Syst Rev; 2011 Jul; (7):CD003510. PubMed ID: 21735394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects.
    Regazzi M; Maserati R; Villani P; Cusato M; Zucchi P; Briganti E; Roda R; Sacchelli L; Gatti F; Delle Foglie P; Nardini G; Fabris P; Mori F; Castelli P; Testa L
    Antimicrob Agents Chemother; 2005 Feb; 49(2):643-9. PubMed ID: 15673746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women.
    Mandelbrot L; Peytavin G; Firtion G; Farinotti R
    Am J Obstet Gynecol; 2001 Jan; 184(2):153-8. PubMed ID: 11174495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy.
    Mirochnick M; Thomas T; Capparelli E; Zeh C; Holland D; Masaba R; Odhiambo P; Fowler MG; Weidle PJ; Thigpen MC
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1170-6. PubMed ID: 19114673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of nelfinavir in an HIV patient with renal insufficiency.
    Izzedine H; Diquet B; Launay-Vacher V; Jouan M; Theou N; Deray G
    AIDS; 1999 Oct; 13(14):1989. PubMed ID: 10513666
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk of congenital cytomegalovirus infection among HIV-exposed uninfected infants is not decreased by maternal nelfinavir use during pregnancy.
    Gantt S; Leister E; Jacobsen DL; Boucoiran I; Huang ML; Jerome KR; Jourdain G; Ngo-Giang-Huong N; Burchett S; Frenkel L
    J Med Virol; 2016 Jun; 88(6):1051-8. PubMed ID: 26519647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life.
    Mirochnick M; Stek A; Acevedo M; Keller M; Holland D; Capparelli E; Connor J; Huang S; Hughes M; Watts H; Mofenson L; Bryson Y
    J Acquir Immune Defic Syndr; 2005 Jun; 39(2):189-94. PubMed ID: 15905735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy.
    Sripan P; Le Coeur S; Ingsrisawang L; Cressey TR; Bouazza N; Foissac F; Ngo-Giang-Huong N; Traisathit P; Srirompotong U; Ayudhaya OP; Puangsombat A; Jungpipun J; Jittayanun K; Tréluyer JM; Jourdain G; Lallemant M; Urien S
    Antivir Ther; 2016; 21(5):435-40. PubMed ID: 26492107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.